News
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
Lindus Therapeutics, a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board of directors as a non-executive director.
.jpeg)
Why working with a university isn't always best for DTx start-ups
Our Co-Founder Michael explores the best options for DTx startups looking to start generating clinical evidence and why it might not always be best to work with academic institutions.
Why I Joined Lindus Health - Emma Ogburn PhD, VP Clinical Operations
To work on innovative trials and accelerate access to treatments. To tackle disparities in research accessibility. To use technology to accelerate studies and work with a motivated team. Hear more from our VP of Clinical Operations, Emma Ogburn PhD, on why she joined Lindus Health.
.jpeg)
Discussing DTx challenges and go-to-market in the UK with Charlotte Lee-Sinclair (ex-Big Health)
A fireside chat, this time by an actual fire! Our conversation with Dr Charlotte Lee-Sinclair is a must-read on DTx challenges and the road to go-to-market in the UK. Read here.
%2520(1).png)
Debunking the 3 biggest myths about decentralised trials
You've probably heard of decentralised clinical trials, but there are a lot of myths out there. Here we debunk the 3 biggest myths.
.jpeg)
Product Clinic #6: Releasing, Fast and Slow
Depending on your background, our 6 to 8 week product release cycle will evoke one of two reactions. If you work in the clinical space: Woah, what an incredibly fast release cycle! But if you work in a typical SaaS startup: How quaint, I release 3 times a day! Heard of Daniel Kahnemann's bestseller Thinking, Fast and Slow? Well, there is our inspiration!
.jpeg)
What taking intravenous ketamine taught me about clinical trial design
In the name of science, our co-founder, Meri Beckwith, took intravenous ketamine as part of a clinical trial. Find out what he has learnt about clinical trial design from his most recent trial experience.
%2520(1).png)
A Fireside Chat with Alex Zhavoronkov, founder of Insilico Medicine, on life, death and ageing
Longevity and the halt of decline may sound like the stuff of dreams that many chase in expensive face creams. But not for Alex Zhavoronkov, a spearhead in ageing and longevity and founder of Insilico Medicine. Read our fireside chat here to learn about Alex's pioneering work in this field.
.jpeg)
The challenge of using open source trial data to drive ML and what Lindus Health is doing differently
It is no secret that many challenges are associated with using open source trial data in machine learning. Read here to find out what we are doing to innovate ML-powered tools to fuel our clinical trials.
%2520(1).png)
Announcing Pilot Trials: clinical data in weeks, not years
Enter pilot trials! We now offer pilot trials for companies who may not need to run a full clinical trial but need data in order to get their product to patients. Sound like it could be you? Read more here.
Why working with a university isn't always best for DTx start-ups
Our Co-Founder Michael explores the best options for DTx startups looking to start generating clinical evidence and why it might not always be best to work with academic institutions.